LNCAR for exosomal transport in renal carcinoma cells

Is the most commonly used clinical treatment option for renal cell carcinoma. However, clinical data show that 10 to 20 percent of patients show resistance to sunitinib. Clinical Sunitinib treatment of renal cancer often appear drug tolerance, what is the reason? What role did lncRNAs play in this process? Our team discovered a long-chain non-coding RNA specific for sunitinib resistance -- lncARSR, which can be transported in the form of exosomes and competitively bind miR-34/miR-449 to regulate AXL and c-Met through ceRNA, thereby regulating sunitinib resistance.